Actively Recruiting
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
Led by Indiana University · Updated on 2025-06-04
100
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. The main questions it aims to answer are: -Is TMP-SMX effective at successfully treating children with invasive infections due to MRSA? What are the side effects of TMP-SMX in children taking it for invasive infections due to MRSA? Researchers will compare TMP-SMX to a clindamycin (a commonly prescribed antibiotic for the treatment of MRSA in children) to see if TMP-SMX works better, worse or the same as clindamycin for children with invasive infections due to MRSA. Participants will: Take TMP-SMX or clindamycin for the treatment of their invasive infection due to MRSA. Will follow up with the provider treating their invasive infection at the discretion of the treating provider. Keep a diary of their symptoms and any side effects of the medicine
CONDITIONS
Official Title
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 60 days and 18 years at the time of oral step-down treatment
- Diagnosed with osteoarticular infection (OAI) or head and neck infection (HNI) confirmed by clinical signs or radiographic evidence
- Treated by the clinical team for confirmed or suspected MRSA infection
- Ready or planned to transition to oral antibiotic therapy
- Symptoms of OAI or HNI less than 14 days at hospital admission
You will not qualify if you...
- Enrollment in another interventional study or receipt of investigational drug within past 30 days
- Known cancer, immunodeficiency, sickle cell anemia, or G6PD deficiency
- Underlying bone disease or presence of hardware/implant in affected area
- Infection caused by penetrating wounds, open fractures, major trauma, foreign body, or post-operative infection
- Spinal osteomyelitis
- Chronic renal, gastrointestinal, liver, or heart disease affecting drug absorption or metabolism
- Inability to take medicine by mouth or via feeding tubes
- More than 14 days of intravenous antibiotic treatment for OAI or HNI
- Inability or unwillingness to consent
- Social or medical conditions that could negatively affect participation
- Allergy to both TMP-SMX and clindamycin
- Known MRSA resistant to both TMP-SMX and clindamycin
- Known pregnancy at enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
Actively Recruiting
Research Team
M
Mary Stumpf
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here